Stay updated with breaking news from Hematology Development. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
First data to be presented as a late-breaker abstract from global pivotal APPLY-PNH trial of investigational oral monotherapy iptacopan in paroxysmal nocturnal hemoglobinaria (PNH), a rare and
Investegate announcements from NOVARTIS AG CHF0.50(REGD), Novartis highlights scientific advances with Kisqali, iptacopan, Scemblix and YTB323 data at SABCS and ASH
First data to be presented as a late-breaker abstract from global pivotal APPLY-PNH trial of investigational oral monotherapy iptacopan in paroxys...
Overall survival results from pooled exploratory analysis of MONALEESA trials in patients with aggressive HR+/HER2- advanced breast cancer treated with Kisqali Data from VISION study reporting associations
15.08.2022 - Phase III CANOPY-A trial did not meet primary endpoint of disease-free survival in patients with stages II-IIIA and IIIB completely resected non-small cell lung cancer1Findings will be presented at an upcoming medical meetingNovartis remains ... Seite 1